Gemcitabine plus sorafenib in patients with advanced pancreatic cancer: a phase II trial of the University of Chicago Phase II Consortium

BACKGROUND: Sorafenib, an inhibitor of B-raf, VEGFR2, and PDGFR-β, has activity against pancreatic cancer in preclinical models. In a phase I trial of gemcitabine plus sorafenib, 57% of pancreatic cancer patients achieved stable disease. PATIENTS AND METHODS: We conducted a multi-center phase II tri...

全面介紹

Na minha lista:
書目詳細資料
發表在:Invest New Drugs
Main Authors: Kindler, Hedy Lee, Wroblewski, Kristen, Wallace, James A., Hall, Michael J., Locker, Gershon, Nattam, Sreenivasa, Agamah, Edem, Stadler, Walter M., Vokes, Everett E.
格式: Artigo
語言:Inglês
出版: 2010
主題:
Article
在線閱讀:https://ncbi.nlm.nih.gov/pmc/articles/PMC4319645/
https://ncbi.nlm.nih.gov/pubmed/20803052
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1007/s10637-010-9526-z
標簽: 添加標簽
沒有標簽, 成為第一個標記此記錄!

相似書籍